LivaNova (LIVN) Cash from Operations Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -84.38% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 185.96% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 16.00% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.60% |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn | -36.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.51% |
| Dec 31, 2025 | 4.69% |
| Sep 30, 2025 | 66.80% |
| Jun 30, 2025 | 45.12% |
| Mar 31, 2025 | 140.12% |
| Dec 31, 2024 | 45.87% |
| Sep 30, 2024 | 181.18% |
| Jun 30, 2024 | 341.71% |
| Mar 31, 2024 | -51.92% |
| Dec 31, 2023 | 188.50% |
| Sep 30, 2023 | -49.11% |
| Jun 30, 2023 | -75.11% |
| Mar 31, 2023 | -19.62% |
| Dec 31, 2022 | -44.14% |
| Sep 30, 2022 | 48.78% |
| Jun 30, 2022 | -139.96% |
| Mar 31, 2022 | 32.56% |
| Dec 31, 2021 | -9.48% |
| Sep 30, 2021 | 176.69% |
| Jun 30, 2021 | 234.77% |
| Mar 31, 2021 | 118.37% |
| Dec 31, 2020 | 1,190.47% |
| Sep 30, 2020 | 111.30% |
| Jun 30, 2020 | 1.94% |
| Mar 31, 2020 | -5,472.09% |
| Dec 31, 2019 | -86.28% |
| Sep 30, 2019 | -249.99% |
| Jun 30, 2019 | -168.92% |
| Mar 31, 2019 | -90.32% |
| Dec 31, 2018 | 18.20% |
| Sep 30, 2018 | 21.28% |
| Jun 30, 2018 | 1,808.74% |
| Mar 31, 2018 | -38.59% |
| Dec 31, 2017 | -56.68% |
| Sep 30, 2017 | 14.53% |
| Mar 31, 2017 | 245.91% |